Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants

    loading  Checking for direct PDF access through Ovid

Abstract

One hundred forty-five infants were vaccinated with 25 μg of pertussis toxoid (NICHD-Ptxd) at 3, 5 and 7 or at 3, 5 and 12 months of age. One month after the third vaccination all had high serum IgG and neutralizing antibodies (antitoxin) against pertussis toxin. Vaccination at 3, 5 and 12 months resulted in higher antibody titers than vaccination at 3, 5 and 7 months. Sera obtained from 109 children at 3 years of age showed a decline of antibodies, but all had detectable antibodies. Adverse reactions were confined to local redness and swelling, which exceeded 2 cm after 17% of all injections.

When the children were 3 years old, a comparison was made of the incidence of clinical pertussis in 142 of the 145 vaccinated children

Related Topics

    loading  Loading Related Articles